相关实验视频

Updated: Jan 17, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

作为安全有效的疫苗的SARS-CoV-2衍生RNA复制品

Marta Villarejo-Torres¹, Iván Nombela-Diaz¹, Diego Muñóz-Santos¹

¹Department of Molecular and Cell Biology, National Center of Biotechnology (CNB-CSIC), Darwin 3, Campus Universidad Autónoma de Madrid, Madrid 28049, Spain.

Proceedings of the National Academy of Sciences of the United States of America

|September 24, 2025

概括

这项研究设计了SARS-CoV-2的新型RNA复制品 (RRs),以获得更安全的疫苗. 用这种RR疫苗候选人的鼻腔免疫保护小鼠免受SARS-CoV-2挑战和变种的影响.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
疫苗开发疫苗开发

背景情况:

严重急性呼吸系统综合征2 (SARS-CoV-2) 构成了严重的全球健康威胁.
现有的疫苗技术在引起广泛和持久的免疫力方面面临挑战.
开发新型疫苗平台对于疫情准备至关重要.

研究的目的:

构建和评估一种来自SARS-CoV-2的新型RNA复制 (RR) 候选疫苗.
在临床前模型中评估RR疫苗的免疫性,安全性和保护功效.
研究RRs在诱导粘膜免疫和对SARS-CoV-2变种的交叉保护方面的潜力.

主要方法:

使用细菌人工染色体的基因工程来创建由SARS-CoV-2衍生的RNA复制品 (RRs),并删除非基本基因.
在实验室中对RR感染的细胞进行病毒样颗粒形成和RNA复制的表征.
用RR候选疫苗对表达人类ACE2的转基因小鼠进行鼻腔免疫接种.
评估幽默和细胞免疫反应,包括抗体产生 (IgG,IgM,IgA) 和T细胞反应 (CD4+,CD8+,记忆T细胞).
通过观察炎症反应和副作用来评估疫苗的安全性.
对表达XBB.1.5尖端蛋白的更新RR进行测试,以中和同源病毒并保护其免受变异.

主要成果:

RR疫苗候选物形成了非分泌的病毒样颗粒,提高了疫苗的安全性.
在长时间内,RRs维持了编码关键病毒蛋白质 (S,M,N) 的RNA生产.
鼻腔免疫诱导了强大的呼吸粘膜免疫力和针对SARS-CoV-2蛋白质的全身抗体反应.
免疫接种提供了对SARS-CoV-2挑战的保护,引起了全面的幽默和细胞免疫力.
同感染证明了RR疫苗对野生型SARS-CoV-2复制的显著抑制.
RR疫苗表现出轻微的炎症反应,没有重大副作用,并且具有良好的温度稳定性.
一个表达XBB.1.5尖端蛋白的更新RR产生了中和抗体,并提供了对最近的SARS-CoV-2变体的全面保护.

结论:

设计的SARS-CoV-2RNA复制体 (RR) 是一个有前途和更安全的疫苗候选人.
鼻内注射RR疫苗有效诱导粘膜和全身免疫力对抗SARS-CoV-2.
该RR疫苗显示了对当前和新出现的SARS-CoV-2变种的广泛保护的潜力,为未来的流行病准备提供了宝贵的工具.

关键词:

在RNA复制器上.这就是SARS-CoV-2病毒.冠状病毒冠状病毒的新冠病毒.疫苗疫苗疫苗疫苗

更多相关视频

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

相关概念视频

Viruses with RNA Genomes

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...